Sironax is an emerging leader in the discovery and development of transformational therapies that address the root cause of age-related degenerative disease. Today, the majority of treatments for these diseases are palliative, with a focus on alleviating symptoms alone. As pioneers in the science surrounding programmed cell death mechanisms and their connection to age-related degenerative disease, Sironax was co-founded in 2017 by Dr. Xiaodong Wang, who recognized the growing need for therapies that could directly address disease pathology.

Since our founding, we have been hard at work developing our pathway-driven portfolio strategy which has enabled us to establish a pipeline of novel therapies that address a wide range of age-related degenerative diseases and underlying mechanisms, including regulated cell death, NAD+ pathway modulations, neuroprotective pathways, neuroinflammation, among others. To date, our pipeline contains more than five innovative programs spanning small and large molecules, all of which are global first-in-class or front-runners. Our lead RIPK1 program is comprised of several chemically differentiated small molecule inhibitors, including SIR9900 and SIR2446, both completed Phase 1a study in healthy volunteers with robust target engagement and well-tolerated safety profile. Another key program of the company is an axon protection small molecule, which has the best-in-class potential, driven by the intrinsic differentiation in inhibitory mechanism. It is currently in Ph1 1a study and preclinical evidence demonstrates strong potential as a transformative therapy for ALS and other neurodegenerative diseases. In parallel, we continue to expand our R&D footprint, with plans to advance additional programs into clinic over the next several years.

With operations in China and the U.S., Sironax presently has 170 employees and growing and we continue to build our global team of highly skilled chemists, biologists, manufacturing experts, biomarker scientists and clinicians. Along with decades of experience in global pharmaceutical R&D, our team shares a collective vision of shifting the treatment paradigm for age-related degenerative disease to ultimately improve the lives of millions of patients and their families around the world.